First human tests begin for new PNH treatment antibody
NCT ID NCT07256301
Summary
This early-stage trial is testing the safety of a new antibody drug called EA5 in adults with PNH, a rare blood disorder. The study will enroll about 24 patients to receive different doses of the drug over several weeks. Researchers will monitor for side effects and measure how the drug behaves in the body and affects the immune system.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNH - PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital, Zhejiang University School of Medicine, Chengzhan Campus
RECRUITINGHangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Institute of Hematology & Blood Diseases Hospital (Chinese Academy of Medical Sciences)
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.